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1Abstract
The FDA should judiciously limit the FDA approval of race-speciﬁc drugs to situations in which the utiliza-
tion of racial categories is based on statistically signiﬁcant scientiﬁc data and necessity and, in such cases,
the meaning of race utilized should be deﬁned. The term “race” is an inherently ambiguous social construct
making the FDA approval of race-speciﬁc drugs and use of race in FDA approval decisions dangerous with
debatable scientiﬁc legitimacy. Further, race is generally used in drug trials as a crude proxy for the deter-
mination of genetic variation, which tends to be both over and under-inclusive in determining the eﬃcacy or
safety of a drug for any individual. The limited genetic validity of race is confounded by the reality that many
population diﬀerences between races may be the result of socio-economic and environmental factors that are
not per se innate or inherent to any racial population. While the scientiﬁc validity of race as biologically
signiﬁcant classiﬁcation is debatable, the general public is likely to interpret the governmental approval of
the drug by the FDA as evidence of inherent genetic diﬀerences between racial groups that will serve to only
further racial discrimination and eugenic ideologies. Thus, the FDA should proceed cautiously by narrowly
tailoring the use of race in the FDA approval of new drugs and require a showing of statistically signiﬁcant
scientiﬁc data and the need to rely on race because of the lack of genetic markers.
Introduction
Life-Saver1
INDICATIONS AND USES
Life-Saver is indicated for treatment in self-identiﬁed Black patients to improve survival, prolong time to
hospitalization, and to improve patient-reported functional status.2
1Life-Saver is merely a hypothetical drug used for discussion in this paper.
2The indication and use statement for Life-Saver is based on the indication and use statement for the ﬁrst “ethnic” drug
BiDil r  provided as a part of the patient information sheet mandated by 21 U.S.C. § 352 (2004). The indication and use
statement for BiDil r  reads, “BiDil is indicated for treatment of heart failure as an adjunct to standard therapy in self-
identiﬁed Black patients to improve survival, prolong time to hospitalization for heart failure, and to improve patient-reported
2Explicitly with our hypothetical drug Life-Saver’s indication and use guidelines, the use of the drug is
approved for treatment in self-identiﬁed Blacks. While the drug purports to improve survival and the general
health of patients, this potentially life saving drug is available under Food and Drug Administration (“FDA”)
approval solely to self-identiﬁed Blacks. While it is true that FDA guidelines allow prescribing drugs oﬀ-
label, which would allow doctors to distribute the drug to individuals who do not self-identify as Black, many
doctors may be hesitant to prescribe to a non-Black person. Doctors may regard the drug as a Black-only
treatment without further investigation into drug research data on a racially diverse patient clinical trial,
clinical trials targeted towards the racial group identiﬁed by their patient, or extensive scientiﬁc knowledge
regarding the mechanism of drug function. As a result, patients who identify with White, Hispanic, Asian,
and other racial groups would be denied or severely limited in their access to our hypothetical drug, Life-
Saver, even though they may beneﬁt from the use of the drug with increased survival and improved general
health. Our hypothetical Life-Saver may seem like only an academic, intellectual exercise into the use of
race in scientiﬁc research and the ramiﬁcations on society. However, with the FDA approval of the heart
medication BiDilr , with a use and indication statement very similar to our hypothetical drug, Life-Saver,
the debate has moved beyond the realm of an abstract academic debate to the real world.3
Currently, peer reviewed scientiﬁc journals report that over twenty-nine diﬀerent medicines (or combination
of medicines) possess diﬀerences in safety and eﬃcacy based on race or ethnicity.4 Although these diﬀerences
based on race and ethnicity are still controversial and strenuously debated within the scientiﬁc community,
the movement to discover and market race and ethnic speciﬁc drugs is growing. The discovery and FDA
approval of drugs, such as BiDilr , which appears to have a racially diﬀerential eﬀect on self-identiﬁed Blacks,
functional status.” BiDil r  Product Insert (2005), available at http://www.bidil.com/pdf/PI.pdf.
3FDA, FDA Approves BiDil Heart Failure Drug for Black Patients (June 23, 2005), available at
http://www.fda.gov/bbs/topics/NEWS/2005/NEW01190.html.
4Sarah K. Tate & David B. Goldstein, Will tomorrow’s medicines work for everyone?, 36 Nat. Genetics S34, S34 (2004).
3shines as a beacon of hope to address potential racial diﬀerences in medical response to drugs and narrowing
the unequal access to medical services. The development of race speciﬁc drugs highlights potentially distinct
medical needs in a racial community. The development of drugs such as BiDilr  and the development of FDA
guidelines permitting approval of such race-speciﬁc drugs, however, should also raise serious concerns as to
the appropriateness of using race in drug development and the economic motives driving drug companies,
at least in part, to target racial groups.
Targeting a drug to a particular racial group creates ﬁnancial incentives for pharmaceutical companies that
may impede access to safe, eﬀective, and cheap treatment to everyone who could beneﬁt regardless of race.
While narrowing the ﬁeld of potential drug users to a minority racial group may seem to narrow the potential
revenue generation abilities of a drug, there may be ﬁnancial incentives lurking in the background motivating
the development of racial drugs. For example, in the case of BiDilr , intellectual property rights may have
in part driven the manufacturer to test the drug in self-identiﬁed Blacks.5 In the initial clinical study of
BiDilr , the drug appeared to have an impact on mortality in a mixed-racial population, however, “the
diﬀerences was only of border-line statistically signiﬁcance.”6 In the second clinical trial, the FDA voted
against approving the drug in a mixed-racial population in a vote of nine to three because “there were too
many variables speciﬁed in the protocols at primary end points for them to interpret the ...data with any
degree of certainty.”7 After the advisory committee denied approval, the BiDilr  inventor went back and
reanalyzed the clinical data from both clinical trials, including 395 black patients and 1024 white patients,
and found that the active ingredients of BiDilr  were “particularly eﬀective” in black patients.8 The U.S.
5See Jonathan Kahn, How a Drug Becomes “Ethnic”: Law, Commerce, and the Production of Racial Categories in Medicine,
4 Yale J. Health Pol’y, L. & Ethics 1 (2004).
6Id. at 12.
7Id. at 15.
8Id. at 17. See Carson P. et al, Racial diﬀerences in response to therapy for heart failure: analysis of the vasodilator-heart
failure trials, 5 J. of Cardiac Failure 178 (1999).
4Patent and Trademark Oﬃce issued a new patent for the use of BiDilr  in African-Americans ﬁnding that
the “race-speciﬁc method of treatment to be a ‘non-obvious’ extension” of the earlier patent application for
the drug.9 Reframing BiDilr  in terms of race, granted BiDilr  creators an opportunity to amend their FDA
new drug application and extend intellectual property rights. As a result of the race-speciﬁc method of treat-
ment, BiDilr  manufacturers will have patent protection until 2020, rather than 2007.10 Targeting BiDilr  to
self-identiﬁed Blacks granted BiDilr  manufacturers thirteen more years of patent protection, while a treat-
ment regime for all patients could not have extended the company’s intellectual property rights.11 Further,
while the indication and use statement indicates the drug is FDA approved as a treatment for self-identiﬁed
Blacks, doctors may still prescribe the drug oﬀ-label to other racial groups, recouping at least some of the
costs of targeting the drug for FDA approval to a smaller population of patients.12 The market of a drug and
attempt to achieve FDA approval of a race-speciﬁc drug may become a business strategy of pharmaceutical
companies motivated by ﬁnancial incentives, rather than purely scientiﬁc data. As more drugs are reported
to possess diﬀerences in safety and eﬃcacy based on race, the economic costs to U.S. patients and health
care insurers in terms of paying higher prices for patented drugs will only grow.
In regards to the appropriateness of race generally in drug discovery, the limited FDA approval of potential
life saving drugs for use in particular racial and/or ethnic groups raises serious questions of fairness and
equality of health care and drug access that cuts both ways in favor and against race-based therapeutics.13
9Kahn, supra note 5, at 32.
10Jonathan Kahn, Misreading Race and Genomics after BiDil, 37 Nat. Genetics 655, 655 (2005). While beyond the scope
of this paper, the policy of the U.S. Patent and Trademark Oﬃce regarding the use of race in patent prosecution should be
reevaluated and revised to limit the use of race-speciﬁc claims.. One could argue that a claim to a racial subpopulation is
obvious and thus unpatentable when compared to prior art disclosing data demonstrating general drug eﬀectiveness regardless
of race; however, as evidenced by BiDil, the PTO currently regards a claim to a racial subpopulation non-obvious even with
prior art demonstrating eﬃcacy in humans generally.
11M. Gregg Bloche, Race-Based Therapeutics, 351 New Eng. J. of Med. 2035, 2036 (2004).
12See Michael I. Krauss, Loosening the FDA’s Drug Certiﬁcation Monopoly: Implications for Tort Law and Consumer
Welfare, 4 George Mason L. Rev. 457, 470 (1996). For example in the case of BiDil, some researchers have indicated that
they are “absolutely conﬁdent that BiDil will work for patients other than African Americans” and should be given to patients
regardless of race with nitric oxide deﬁciencies. David Rotman, Race and Medicine: Population Genomics is Expanding our
Knowledge of Human Diversity. What Role Should Race Have in Drug Development, Technology Review (April 2005), available
at http://www.technologyreview.com/read article. aspx?id=14301&ch=biotech
13See Erik Lillquist and Charles A. Sullivan, The Law and Genetics of Racial Proﬁling in Medicine, 39 Harv. C.R.-C.L. L.
5Notably, minority populations traditionally have less access to health care services, and most FDA-approved
drugs currently on the market were tested in clinical trials on a patient populations consisting primarily
of Caucasians.14 There are still substantial inequalities and unfairness in access to health care as a result
of socioeconomic status and discrimination that disproportionately aﬀect individuals based on race. Thus,
drugs targeted to traditionally underserved minority racial groups could improve general health care services
for these populations by increasing funding to explore diseases that disproportionately aﬀect the minority
individuals and increase the knowledge in the minority community of treatment options. However, a funda-
mental question remains whether the recent embrace of race-based therapeutics by the medical community
and FDA is justiﬁed scientiﬁcally, and whether self-identiﬁed race and/or ethnicity, alone as a proxy for ge-
netic variation, should be utilized as categories to distinguish individuals in medical research and FDA drug
approval processes. Further, beyond the scientiﬁc legitimacy of use of race as a proxy for genetic variation,
the use of race as a basis of FDA approval creates its own fairness and equality issues by potentially limiting
access of other racial groups to drugs and by reinforcing and legitimatizing dangerous social beliefs that race
represents inherent, genetic diﬀerences, which could serve as a basis for further racial discrimination. There
may be circumstances where a drug, which fails to meet FDA eﬀectiveness and safety guidelines for the
general population, but does for a discrete racial population, should be approved by the FDA with labeling
indicating racial diﬀerences in eﬃcacy or side-aﬀects upon a showing of statistically signiﬁcant clinical data
denoting diﬀerences between racial populations. However, the FDA should be cautious and should signiﬁ-
cant limit the race-speciﬁc FDA drug approval applications to situations where there is a scientiﬁc basis and
necessity for the use of race because no other population markers are available (i.e. genetic markers), and
in such cases, the meaning of race utilized should be clearly deﬁned.
The judicious and limited FDA approval of race-speciﬁc is appropriate based on four lines of reasoning that
Rev. 391, 396-97 (2004); see also Troy Duster, Race and Reiﬁcation in Science, 307 Sci. 1050, 1050 (2005).
14See David Wendler et al., Are Racial and Ethnic Minorities Less Willing to Participate in Health Research?, PLOS Med.
3(2): 1, 7-8 (2006).
6will be discussed in this paper. First, race, particularly self-identiﬁed race, is an inherently ambiguous social
construction making use in FDA approval reviews dangerous. Secondly, race is merely a crude proxy for the
determination of genetic traits, which results in over and under-inclusion of certain individuals in categories
where a drug may be eﬃcacious. Third, population diﬀerences based on race may often be the partial result
of socio-economic and environment factors, not genetic factors, weakening the scientiﬁc argument that race
alone is an appropriate indicator of drug eﬃcacy or risk. Fourth, while arguably the scientiﬁc community
may be able to practice restraint and recognize the limitations of using race, the lay community may interpret
diﬀerences in disease risk and FDA approval of race speciﬁc drugs as inherent diﬀerences as the genetic level
among racial groups and serve as the basis for discriminatory and eugenic policies. Because of the foregoing
reasons, as will be discussed in the ﬁnal section of this paper, the FDA should revise its policies regarding
the FDA drug approval race-speciﬁc drug applications to situations where race is clearly deﬁned and there
is clear scientiﬁc basis and necessity to ensure that potentially life saving drugs are made available to all
regardless of race.
Race: An Ambiguous Social Construct
Undeniably, race is an important and volatile social construct within the United States. Race continues to
serve as the basis for discrimination and represents a key dimension of the economic and social stratiﬁcation
of our society. Race not only plays an important role within American society generally, but also within the
medical and health care communities. For example, Blacks in the United States generally receive lower quality
health care than White patients. A study in the New England Journal of Medicine monitoring Medicare
7beneﬁciaries reported that Black patients were less likely to receive health care services from a board certiﬁed
physician than White patient.15 Further, the rates of early screening for most diseases was lower in Black
patients compared to White patient, while Black patients were more likely to be diagnosed with a disease
at relatively advanced stages.16 Another study reported in the New England Journal of Medicine indicated
that Black patients were signiﬁcantly less likely to undergo angioplasty and bypass surgery than White
patients—a diﬀerence in application of coronary-revascularization procedures that could not be explained by
clinical characteristics of the disease.17 Race in the United States as evidenced by these studies is a social
construct with real, signiﬁcant implications in one’s access to quality health care.
While Americans recognize the power of the race construct in society, there is substantial ambiguity in
deﬁning race and which characteristics and factors should be considered in the deﬁnition of race. Further,
the guidelines delineating the contours of the race are not static, but have changed throughout United States
history. Currently the FDA recommends the use of the standardized Oﬃce of Management and Budget
(OMB) race and ethnicity categories for data collection (Policy Directive 15).18 The OMB procedures
recommend using a two-question format for gathering information on race and ethnicity. The ﬁrst question
to ask is whether the individual self-identiﬁes with the Hispanic or Latino ethnic group.19 The second
question is whether the individual self-reports to be a member of one of ﬁve racial categories: (1) American
Indian or Alaska Native, (2) Asian, (3) Black or African American, (4) Native Hawaiian or Other Paciﬁc
Islander, and (5) White.20 The ﬁve diﬀerent racial groups encompass individuals within each single racial
group from diverse geographical ancestry. White reﬂects individuals with ancestry in Europe, Middle East,
15See Peter B. Bach et al., Primary Care Physicians Who Treat Whites and Blacks, 351 New Eng. J. of Med. 575 (2004)
(all patient were Medicare beneﬁciaries).
16Id. at 583.
17See Eric D. Peterson et al., Racial Variation in the Use of Coronary-Revascularization Procedures — Are the Diﬀerences
Real? Do They Matter?, 336 New Eng. J. of Med. 480 (1997) (all patients utilized the Duke University Medical Center).
18See FDA, Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials (Sept. 26, 2005),
available at www.fda.gov/CbER/gdlns/racethclin.htm.
19See id. at 5.
20See id.
8or North Africa, while Asian includes people from geographical areas ranging from India and Pakistan to
Japan.21 Beyond the ﬁve racial categories, the OMB allows an individual to identify themselves with more
than one racial group.
The current guidelines dividing U.S. citizens into ﬁve racial groups and one ethnic group was established in
1997 by the OMB Federal Standards for Racial and Ethnic Data in preparation for the 2000 Census. This
1997 Policy Directive 15 modiﬁed a 1977 Directive in which Asian and Paciﬁc Islander was considered a single
racial group to recognize Asian as a separate racial group from Native Hawaiian and Other Paciﬁc Islander.22
Further, the 1997 Policy Directive 15 allowed multiracial individuals to mark on or more racial categories on
forms for the ﬁrst time.23 Before this change, individuals of mixed racial ancestry were forced to select only
race, even if they self-identiﬁed with multiple racial groups. The change in U.S. policy regarding classiﬁcation
of race is not the ﬁrst. The federal government utilized race characterization in census calculations since
1790.24 The Census Bureau has utilized multiple methods through history to categorize race based on
national origin, tribal associations, and physiological characteristics such as skull size, skin color, and facial
features.25 Historically, terms like mulatto, quadroon, octoroon were utilized to classify individuals based
on percentage of Black ancestry, which emerged as an extension of the “one drop” of African ancestry
determining racial category.26 Further, in the beginning of the twentieth century, Jews were classiﬁed as a
distinct, non-White race.27 As the U.S. Census guidelines regarding categorization of race illustrate, race is
an ambiguous concept subject to societal change over time.
The struggle and changing social norms regarding deﬁning race in American culture is further illustrated
21See Office of Mgmt. & Budget, OMB Standards for Maintaining, Collecting, and Presenting Federal Data
on Race and Ethnicity (Oct. 30, 1997), available at www.Whitehouse.gov/omb/inforeg/re app-a-update.pdf
22Vickie M. Mays et al., Classiﬁcation of Race and Ethnicity: Implications for Public Health, 24 Annual Rev. of Public
Health 83 (2003).
23Id.
24Id. at 88.
25Sandra Soo-Jin Lee et al., The Meaning of “Race” in the New Genomics: Implications for Health Disparities Research, 1
Yale J. Health Pol’y, L. & Ethics 33, 37 (2001).
26Mays, supra note 22, at 88.
27Id.
9within Supreme Court jurisprudence. In Saint Francis College v. Al-Khazraji, 481 U.S. 604 (1987), the
Supreme Court of the United States wrestled with the problem of deﬁning the term “race.” Al-Khazraji
was a person of Arab ancestry who alleged being terminated from his position as a university professor
based on race discrimination and brought a cause of action under 42 U.S.C. § 1981.28 § 1981 grants all
person the same rights to make and enforce contracts as White citizens.29 Although § 1981 does not use the
word race in its text, the Court has construed the section to forbid all racial discrimination when making
private and public contracts.”30 Saint Francis College argued that Al-Khazraji falls within the classiﬁcation
boundaries of a Caucasian individual and, therefore, according to St. Francis, Al-Khazraji could not allege
racial discrimination when the college denied tenure in favor of another Caucasian professor.31 The Court
states that race should be determined as would be understood by one when § 1981 became law in the
nineteenth century. The Court continues by noting that encyclopedias and dictionaries in the nineteenth
century considered Mongolians, Russians, Spanish, Italians, Germans, Norwegians, Swedes, Gypsies, Anglo-
Saxon, and Arabs as separate races.32 Recognizing that the meaning of the term race has changed over time,
the Supreme Court interprets the legislative intent of the § 1981 statute to protect individuals from intention
discrimination based on their ancestry or ethnic characteristics and hold that a person of Arab ancestry is
protected from discrimination under §1981.33
The Al-Khazraji case illustrates two important points. First, the reality that race is a social construct that
is subject to changing meaning over time as cultural attitudes change. Within the past hundred years,
the notion of race and the term “Caucasian” has changed drastically. Individual countries in Europe were
28See St. Francis College v. Al-Khazraji, 481 U.S. 604, 604 (1987).
29See id. at 609.
30See Runyon v. McCrary, 427 U.S. 160, 168 (1976).
31See Al-Khazraji, 481 U.S. at 609-10.
32See id. at 611-12.
33See id. at 613.
10considered populated by distinct races, rather than the assumption today that Europeans are members of
a single race. The second point is the breadth and ambiguity of terms such as Caucasian. Caucasian,
according to the 1997 Policy Directive 15, includes any individual with ancestry from Europe, Middle East,
or North Africa. As evidenced by the Al-Khazraji case, the term race is ambiguous. § 1983 used the term
“White citizen” in attempt to set a threshold for right to contract. However, through the expansive scope
and ambiguity associated with current racial categories, the text of the statute is unable to articulate its
intended purpose. Whether one wants to label the discrimination as ethnic or race (noting that Arab, for
example, is not recognized as an ethnic group in the 1997 Policy Directive 15), American society view some
subset of our current social construct of race, Caucasian, diﬀerently.34 Race is an inherently ambiguous
social construct as evidenced by the contours of the term and classiﬁcation of race in the United States
throughout its history.
The assignment of an individual to a racial group is not necessarily a “Black and White” issue. The use of
self-identiﬁcation in determining race assumes that individuals know their complete racial ancestry. First,
self-identiﬁcation by an individual with a racial or ethnic group may not represent the true complexity of a
person’s ancestry. Some studies indicate that African Americans possess “a range of European ancestry that
extends from nearly 0 percent to greater than 50 percent”35, with an average according to other studies of 20
percent.36 Additionally, Latinos often comprise an ancestry from three diﬀerent continents, Europe, Africa,
and America, in variable proportions.37 Secondly, many Americans identify with multiple racial categories
of ancestry. According to the 2000 Census, over 6.8 million Americans self-identiﬁed with two or more
races.38 There are no data regarding the growth of the multiracial population in the United States (the 2000
34The OMB speciﬁcally declined to add Arab or Middle Eastern as an ethnic group in the 1997. Office of Mgmt. &
Budget, Revisions to the Standard for the Classification on Federal Data on Race and Ethnicity, (Oct. 30, 2000),
available at http://www.census.gov/population/www/socdemo/race/Ombdir15.html.
35Moumita Sinha et al., Self-reported Race and Genetic Admixture, 354 New Eng. J. of Med. 421 (2006).
36Xiaofeng Zhu et al., Admixture mapping for hypertension loci with genome-scan markers, 37 Nat. Genetics 178 (2005).
37Esteban Gonzalez Burchard et al., Latino populations: a unique opportunity for the study of race genetics, and social
environment in epidemiological research, 95 Am. J. of Pub. Health 2161 (2005).
38See Nicholas A. Jones and Amy Symens Smith, The Two or More Races Population: 2000, Census 2000 Brief, November
11Census was the ﬁrst where an individual could indicate membership in more than one race). However, based
on Census Bureau research regarding children living in mixed-racial families, the population of multiracial
individuals is likely growing. In 1970, only 460,000 children lived in mixed-race families, while in 1990 that
number increased to 1,927,496 children.39 The concept of distinct racial categories is confounded by the
increasing number of multiracial individuals and the number of individuals that with ancestry from multiple
racial groups even though they self-identify with one racial group. With the ever changing deﬁnition of race
and the further growth of a multiracial population within the U.S., “it is extraordinarily diﬃcult to classify
individuals accurately and consistently for the purposes of identifying diﬀerences in drug eﬀects” during
clinical trials.40 Recognizing race as an evolving social construct, the FDA and the health care profession
should be hesitant and cautious about relying on race during clinical trials and in the FDA drug approval
process.
Race and Genetics
Almost since the dawn of modern evolutionary theory and genetics, people have attempted to validate social
and cultural racial distinction by showing that the categorization of individuals was also based on biologi-
2001 page 2.
39See U.S. Census Bureau, Questions and Answers for Census 2000 Data on Race (Mar. 14, 2001), available at
http://www.census.gov/Press-Release/www/2001/raceqandas.html. “The number of children in mixed-race households was
obtained by cross-tabulating the race of the child by the race of the mother and father in married-couple households for the
four major race groups (White; Black; American Indian, Eskimo and Aleut; and Asian and Paciﬁc Islander). Children under 18
years old in married-couple families were identiﬁed as residing in a mixed-race household if the race for the parents, step-parent
or unmarried partner and child living in the household are diﬀerent, or if the race reported on the census form for the child
diﬀer from that of at least one parent, step-parent or unmarried partner.” U.S. Census Bureau, Interracial Tables (Aug.
1, 2002), available at http://www.census.gov/population/www/socdemo/interrace.html. Please note, however, the number
of multiracial families is likely not completely correlative with number of families with multiracial children as individuals who
adopt bi-racially will also be included in this number, even though the adopted children may identify with a single racial group.
40Susanne B. Haga and J. Craig Venter, FDA Races in Wrong Direction, 301 Sci. 466, 466 (2003).
12cally diﬀerences at the genetic level. Race has been used to justify the inferiority of groups of individuals
based, not only on skin color and physiognomy, but also other characteristics, such as intelligence.41 While
race is an undeniably inﬂuential social construct, the scientiﬁc, biological basis of race and whether such a
basis exists is much more contentious. On one hand, some scientists, as illustrated in an editorial in the
New England Journal of Medicine, ﬁnd that “race is a social construct, not a scientiﬁc classiﬁcation[,]”
arguing that “race is biologically meaningless.”42 Conversely, other scientists, as illustrated in a companion
editorial in the same issue of the New England Journal of Medicine, indicated that there are racial and
ethnic diﬀerences in drug responses and diseases, which in part represent biological and in particular genetic
diﬀerences.43 Although the FDA has approved a drug for indications and uses in distinct racial groups, the
scientiﬁc community is still actively debating the biological importance of race and the extent to which race
should be used in scientiﬁc research to represent biological diﬀerences.
The premise that race is biologically meaningless or at the most of marginal signiﬁcance is based upon the
rational that an individual’s racial group membership does not necessarily correlate with an individual’s
genotype. The recent sequencing of the human genome and some population genetics research support this
proposition. According to the American Anthropological Association, modern humans “appear to be a fairly
recent and homogeneous species” with “a high degree of similarities from a biological perspective.”44 The
homogeneous nature of the human species is evident from the reports by the Human Genome Project. Upon
the mapping and sequencing of the human genome, researchers associated with the Human Genome Project
highlighted the ﬁnding that the human population shares 99.9% of its DNA.45 Of the 0.1% of DNA not
41Lillquist, supra note 13, at 409.
42Roberts S. Schwartz, Racial Proﬁling in Medical Research, 344 New Eng. J. of Med. 1392, 1392 (2001).
43Alastair J.J. Wood, Racial Diﬀerences in the Response to Drugs—Pointers to Genetic Diﬀerences, 344 New Eng. J. of
Med. 1393, 1394 (2001).
44American Anthropological Association, American Anthropological Association Response to OMB Directive 15:
Race and Ethnic Standards for Federal Statistics and Administrative Reporting (Sept. 1997), available at
http://www.aaanet.org/gvt/ombdraft.htm.
45J. Craig Venter et al., The Sequence of the Human Genome, 291 Sci. 1304, 1348 (2001).
13shared, greater genetic variation exists within racial and ethnic groups than between them.46 To illustrate
this ﬁnding, take for example a study comparing genetic variation among individuals with ancestry from
the continents of Africa, Europe, and Asia. Approximately 85-90% of genetic variation is found within con-
tinental groups while only an additional 10-15% variation is found between them.47 The extensive genetic
variation among individuals within a continental group makes race an inappropriate proxy genetic risk during
FDA clinical trials and drug approval process. For many genes, allelic variation within a racial population
will often make race an inaccurate predictor of response to drugs or other medical treatments. Therefore,
because of the high degree of overall sequence similarity among the human population and the substantial
genetic variation within racial groups, some researchers argue that race is biologically meaningless or of
marginal signiﬁcance as applied to medical research.
While there is scientiﬁc data that race is of marginal biological signiﬁcance, there is also data that clearly
indicates that genetic traits and susceptibility to disease can diﬀerential eﬀect racial populations. Scientiﬁc
research supports the notion that race and ethnic categories do correlate or represent at least crude prox-
ies for genetic traits that are distinguishable among racial populations. In some instances, the race of an
individual will correlate with genetic characteristics that can result in diﬀering propensities to develop a
disease or response to a drug treatment regime. The scientiﬁc literature is full of report of race or ethnic
diﬀerences in response to drugs and course of disease progression. For example, while the claims are con-
troversial and there is no medical consensus, at least twenty-nine medicaments are claimed in peer reviewed
scientiﬁc journals to have diﬀerences in safety and eﬃcacy based on race or ethnicity.48 Additionally, “[t]he
human population is no homogeneous in terms of risk of disease.”49 Scientists have identiﬁed the genetic
basis of some disease that disproportionately aﬀect special racial groups. Hemochromatosis, a disease that
46Haga, supra note 40, at 466.
47Lynn B. Jorde & Stephen P. Wooding, Genetic variation, classiﬁcation and ‘race’, 36 Nat. Genetics 528, 528 (2004).
48Tate, supra note 4.
49Neil Risch et al., Categorization of humans in biomedical research: genes, race and disease, Genome Biology 3(7):
comment2007.1, comment2007.1 (2002).
14causes the body to absorb and store too much iron, “is associated with a mutant allele (C282Y) found in
all European groups ..., but is virtually absent in non-White groups.”50 Cystic Fibrosis (CF), a disease
causing several lung and nutritional deﬁciencies, is the result of another mutant allele (∆508-CFTR), which
primarily aﬀects people Caucasian, with one out of every 3,200 White babies being aﬀected. In comparison,
within other racial groups, one in every 10,500 Native Americans, one in every 14,000 to 17,000 African
Americans, and one in every 25,500 Asians are aﬀected with CF.51 Another example, Sickle Cell Anemia, is
caused by a variant in the β-globin gene (Hb S variant), which results in abnormal red blood cell shape that
can deprive tissue of oxygen and disproportionately aﬀects Blacks in the United States. The disease aﬀects
approximately 72,000 individuals within the United States with one out of every 500 African Americans
being aﬀected by the disease.52 Research has proven that some genetic diseases are more prevalent within
distinct racial groups.
Race can also indicate diﬀerences in drug metabolism that will aﬀect the eﬃcacy of drug treatment regimes.
Increasingly, researchers are identifying genes, whose allelic frequencies vary signiﬁcantly between ethnic and
racial populations, which inﬂuence the response and metabolism of drugs. For example, N-acetyltransferase
2 (“NAT2”) is an enzyme “involved in the detoxiﬁcation of many carcinogens and the metabolism of many
common drugs.”53 Depending on an individual’s NAT2 genotype, they may be either a slow acetylator or
rapid acetylator, which inﬂuences the rate of detoxiﬁcation and drug metabolism. A recent population-based
study of NAT2 indicated that the slow acetylation phenotype frequency varied based on race with approx-
imately fourteen percent of Asians, thirty-four percent of Black Americans, and ﬁfty-four percent White
50Esteban Gonz´ alez Burchard et al., The Importance of Race and Ethnic Background in Biomedical Research and Clinical
Practice, 348 New Eng. J. of Med. 1170, 1172 (2003).
51American Lung Association, Cystic Fibrosis (CF) Fact Sheet, December 2004, available at
http://www.lungusa.org/site/pp.asp?c=dvLUK9O0E&b=35042#three.
52Melanie Osby & Ira A. Shulman, Phenotype Matching of Donor Red Blood Cell Units for Nonalloimmunized Sickle Cell
Disease Patients: A Survey of 1182 North American Laboratories, 129 Archives of Pathology & Laboratory Med. 190,
190 (2005).
53Buchard, supra note 50, at 1173.
15possessing the slow acetylation phenotype.54 The genetic variation of NAT2 between racial populations is
important to establish as it may help doctors better predict diﬀerences in toxic eﬀects of drugs based on
race.55 As these examples illustrate, race can be indicative of relative genetic risk of some diseases and
response to drug treatment regimes.
While race can indicate genetic diﬀerences that will result in diﬀerential responses to drug treatments or sus-
ceptibility to disease, the genetic basis of drug response or disease susceptibility and the correlation with race
is scientiﬁcally complex. Herein lies the problem—neither argument that race is meaningless or that race cor-
relates with genetics with genetic traits—is completely correct. First, ancestry probably matters more than
OMB deﬁned race. Genetic variations among populations, for example racial populations, generally arise
as the result of geographical isolation and limited admixture among members of the isolated populations.
“Geographically localized populations clearly have diﬀerent frequencies for many disease-related genetics
variants.”56 The primary point of scientiﬁc contention is whether race as deﬁned by continental populations
is a useful unit in assuming genetic similarity. Transfer of genetic variations among continental populations,
which form the basis of the U.S. OMB racial classiﬁcations, historically has been limited by geographical dis-
tance based on shear distance. In boundary areas, however, such as Northern and Eastern Africa, where there
was more admixture of individuals from the European and African continent, the gene frequency in these
populations does not easily fall into distinct Caucasian or Black categories.57 For example, Ethiopians and
Somalis “have greater genetic resemblance to Caucasians and are clearly intermediate between sub-Saharan
Africans and Caucasians.” 58 Characterizing individuals of Ethiopian or Somalian decent as either Black or
Caucasians fails to adequately take into account their genetic background. Similarly, these individuals will
54Mimi C. Yu et al., Acetylator Phenotype, Aminobiphenyl-Hemoglobin Adduct Levels, and Bladder Cancer Risk in White,
Black, and Asian Men in Los Angeles, California, 86 J. of Nat’l Cancer Inst. 712, 712 (1994).
55Buchard, supra note 50, at 1173.
56Richard S. Cooper, Race, Genes, and Health, New Wine in Old Bottles?, 32 Int’l J. of Epidemiology 23, 24 (2003).
57Genetic admixture of races has also been scientiﬁcally well documented in central Asia. See Burchard, supra note 50, at
1173.
58Risch, supra note 49, at comment2007.5.
16likely show a genetic propensity for a disease or response to a drug treatment regime that cannot easily be
classiﬁed as White or Black. This is but one example of countries with known admixture. While there are
continental diﬀerences in allelic frequency, the use of race, particularly as articulated by OMB and utilized
by the FDA, for individuals with ancestry from regions of the world with signiﬁcant admixture response to
drugs will similarly likely be intermediate and distinctly fall within racial classiﬁcation.
Further, while geography often limits transfer of genetic variation among populations, there may also be other
social or culture characteristics that limit admixture among groups within a single racial category. Ashkenazi
Jews, for instance, are classiﬁed as Caucasian, but are genetically at higher risk for many diseases than the
Caucasian population generally. This is likely because the population “descended from a relatively small
number of founders and have remained endogamous for a large part of their history.”59 For example, females
possessing a mutation allele (BRCA1) in high-risk pedigrees have an 80-90% risk of developing breast cancer
and a 40-50% risk of developing ovarian cancer over their lifetime.60 The frequency of BRCA1 mutations
is only 1 in 1666 in the general populations; however, women of Ashkenazi Jewish ancestry possess BRCA1
mutations at a frequency of 1 in 107.61 As illustrated by the Ashkenazi Jews example, characterizing
an individual as Caucasian without further analysis into the individuals sub-group ancestry will fail to
acknowledge and treat potential medical risks because the use of race is both under and over-inclusive. This
is but one example of how race fails to adequately approximate genetic risk. This likely does not represent
an isolated case as “there can be considerable genetic heterogeneity within a [large geographical] region.”62
Relying on the racial group to approximate the genotype is dangerous as it may not be an accurate statement.
59Burchard, supra note 50, at 1172.
60Jeﬀery P. Struewing et al., The carrier frequency of BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi
Jewish individuals, 11 Nat. Genetics 198, 198 (1995).
61Lee, supra note 25, at 34.
62Sarah A. Tishkoﬀ & Kenneth K. Kidd, Implications of Biogeography of Human Populations for ‘Race’ and Medicine, 36
Nat. Genetics S21, S26 (2004).
17Individuals whose genotype fails to correlate with the genotype of their racial group may be at risk for a
disease or fail to take advantage of a drug treatment regime because they do not ﬁt the genetic, racial
stereotype. Race can be informative in a very crude manner as to the genetic propensity of an individual to
develop a medical condition or response to a medical treatment, but there are also signiﬁcant limitations as
to the extent race is a proxy for genetic traits.
Secondly, the extent to which race should be relied upon by medical researchers and the FDA in approving
race-speciﬁc drugs is further complicated by the problem of over and under inclusion of individuals in medical
categories for disease susceptibility or drug response based on race. Genetic variation for complex disease
is continuous, meaning that the phenotype variation resulting from genetic diﬀerences “among groups are
graded, as opposed to dichotomous.”63 Most diseases are not caused by a single mutation in one gene;
rather the genetic basis of complex diseases such as heart disease, cancer, and diabetes are inﬂuenced by “a
combination of polymorphisms in at least several genes, each of which has a small eﬀect.”64 For these type
of complex diseases, disease susceptibility or drug response will not likely fall into two discrete categories,
one “Black” and one “White.” Rather, the response will be graded because multiple genes and alleles of
genes are contributing to the phenotypic eﬀect. While the average disease susceptibility or drug treatment
response for any racial group may be distinct, individuals regardless of race will likely vary along a phenotypic
continuum. Some portion of the members of the racial group will inevitably fail to exhibit the stereotyped
disease susceptibility or drug response resulting in over inclusion of individuals in a medical category based
on race regardless of actual susceptibility or response. Further, there is the potential of under and over
inclusion of individuals for genetic risk of disease or genetic appropriateness of treatment because of their
63Tate, supra note 4, at S37.
64Michael Bamshad et al, Deconstructing the Relationship Between Race and Genetics, 5 Nat. Reviews Genetics 599, 607
(2004).
18race. “Human populations diﬀer from one another almost entirely in the vary proportions of the allelic
genes of the various sets of hereditary factors, and not in the kind of genes they contain.”65 The overall
frequency of alleles in a racial population may vary among racial groups, but some individuals among racial
population will share the same gene allele. “Membership in a genetically inferred cluster [i.e. racial group]
does not mean that all members of the cluster necessarily have a similar genetic composition.”66 Regardless
of how the racial lines are drawn, race can only be a proxy for actual individual genotype. As a proxy, race
will inevitably fail to include all members possessing a particular disease genotype and be over inclusive in
some regards by including individuals who diﬀer genetically with respect to the gene or genes of interest.
All members of a race, however deﬁned, are not genetically identical, and members of diﬀerent races are not
completely genetically diﬀerent.
Most researchers recognize that race is merely a crude proxy for an individual’s actual genetic composition.
Ideally, pharmacogenomics, an analysis of the correlation of an individual patient’s DNA sequence, rather
than that of an ill-deﬁned racial group, to response of drug treatment, should be utilized. Pharmacogenomics
allows the “matching of medicines with the genetic makeup of an individual, to ensure use of medicines
most likely to be eﬀective and least likely to produce adverse drug reactions.”67 In the realm of drug
metabolism and cancer biology, pharmacogenomics has already shown great promise.68 For example, the
FDA has approved a pharmacogenomic drug, Herceptinr , which is a breast cancer treatment, on September
28, 1998.69 Patients diagnosed with breast cancer are genetically screened to determine if they have a
mutation resulting in over expression of the protein HER-2. Only patients over expressing HER-2 will be
65Morris W. Foster and Richard R. Sharp, Race, Ethnicity, and Genomics: Social Classiﬁcations as Proxies of Biological
Heterogeneity, 12 Genome Research 844, 844 (2002).
66Bamshad, supra note 64, at 607.
67Tate, supra note 4, at S38.
68Michelle Meadows, Genomics and Personalized Medicine, 39 FDA Consumer Magazine (2005), at
http://www.fda.gov/fdac/features/2005/605 genomics.html.
69See FDA, Trastuzumab, Genentech Herceptin Approval Letter (September 25, 1998), at
www.fda.gov/cder/foi/appletter/1998/trasgen092598l.pdf (last visited Mar. 28, 2006)
19prescribed the drug, as Herceptinr  is only eﬀective in those patients.70 The problem with pharmacogenomics
and personalized medicine is that researchers need to know the molecular lesion(s) involved in the disease
condition or that aﬀects drug eﬃcacy in order to implement the practice. “For complex diseases ..., little
progress has been made towards understanding any genetic basis within- or between-group variation.”71
This is in part due to the fact that the ability of researchers “to predict accurately [complex traits] (even
given genotypes for a subset of genes) is much lower than for more simply inherited traits.”72 Actually
knowing the particular disease gene responsible or that contributes to disease susceptibility or drug eﬃcacy
is a scientiﬁcally diﬃcult and long process. Thus, race-based pharmacogenomics and diagnostics arise from
“the fear that the promise of so-called personalized genetic medicine is increasingly unlikely to be fulﬁlled
in the near-term future” and will prove a too costly research endeavor. 73 The scientiﬁc diﬃculty and cost
in determining the gene of action associated with personalized medicine does not in itself justify the use of
race as a crude marker for an individual’s genotype.
The fear of reliance upon race, rather than an individual’s genotype or even ancestry, is that society and the
medical ﬁeld will begin to see a disease as racialized and fail to promptly diagnosis or oﬀer treatments to
patients based on racial stereotypes. As discussed in this section, the ambiguous, genetically questionable
reliance on continental racial categorization creates an issue of over and under-inclusion of individuals at
genetic risk for a particular disease or potentially genetically responsive to a drug treatment regime. To
illustrate these principles, take for example sickle cell anemia, a mutation in the β-globin gene. As previously
mentioned, an African American newborn in the U.S. has a one in 500 chance of being aﬀected by the
disease.74 African-Americans have a high risk of being born with sickle cell anemia; however, sickle cell
70See Michael B. Losow, Personalized Medicine & Race-Based Drug Development: Addressing Minority Health Care Dis-
parities In An Ethically Charged Area, 20 St. John’s J. Legal Comment. 15, 21 (2005).
71Joanna L. Mountain and Neil Risch, Assessing Genetic Contributions to Phenotypic Diﬀerences Among ‘Racial’ and
‘Ethnic’ Groups, 36 Nat. Genetics S48, S51 (2004).
72Id. at S52.
73C. Condit and B. Bates, How Lay People Respond to Messages about Genetics, Health, and Race, 68 Clinical Genetics
97, 98 (2005).
74See Osby & Shulman, supra note 52, at 190.
20anemia aﬀects not only member of the Black racial group and does not aﬀect all Blacks equally. Blacks
from southern regions of the African continent generally do not carry the genetic mutation associated with
sickle cell anemia.75 Further, while the rate of sickle cell anemia is extremely low in Caucasians and Asians
generally, sickle cell anemia is relatively common among people with ancestry from Mediterranean countries
such as Greece and Turkey and the Asian country, India.76 Viewing sickle cell anemia as a Black disease
is dangerous in that patients who do not ﬁt the racial categorization associated with the disease may be
misdiagnosed and not get timely treatment.77 Sickle cell anemia is genetically relatively easily identiﬁed
as the disease is cause by a point mutation in a single gene. “ Once the aﬀected gene is known, anybody
can be tested for the disease causing mutation. Race becomes irrelevant.”78 Color-blind genetic testing of
infants, which is universally required in 49 of the 50 states for sickle cell, can detect sickle cell anemia early
minimizing the risk of misdiagnosis based on racial stereotypes.79 For many diseases, genetic testing is not
possible as multiple genes may contribute to the risk of the disease or the molecular lesion(s) associated with
the disease are unknown. Thus, patients rely upon medical expertise to ensure that are correct diagnosed
and properly treated. The FDA should proceed cautiously in approving race-speciﬁc drugs as creation of
racially specialized drug treatments or indirectly the development of racialized diseases has the potential to
delay both diagnosis and treatment of patient relying on the FDA to ensure the safety and eﬃcacy of drugs.
Race and Environment
75See Rotman, supra note 12. Most African-Americans have ancestry that migrated to the United States from West Africa
as a result of the slave trade in early America. See Bamshad, supra note 64, at 605.
76See Schwartz, supra note 42, at 1393; see also D. Mohanty & M.B. Mukherjee, Sickle Cell Disease in India, 9 Current
Opinion Hematology 117, 117 (2002).
77See Frank E. Shafer et al., Newborn Screening for Sickle Cell Disease: Four Years of Experience from California’s Newborn
Screening Program, 18 J. Pediatric Hematology Oncology 36, 36 (1996) (“The prevalence and ethnicity data presented here
[in the study] demonstrate the ineﬀectiveness of targeted screening [based on race or ethnicity] and justify universal screening.”)
78Gregory A. Petsko, Color Blind, 5 Genome Biology 119, 120 (2004).
79National Newborn Screening and Genetics Resource Center, National Newborn Screening Status Report: U.S. National
Screening Status Report Updated 03/03/06, at http://genes-r-us.uthscsa.edu/nbsdisorders.htm (last visited Mar. 25,
2006).
21Racial diﬀerences in drug response and disease symptoms will likely be signiﬁcantly inﬂuenced by environ-
mental factors that are not innate or represent a genetic predisposition. Epidemiologically, reporting and
understanding environmental factors with a higher prevalence in some racial groups and the correlation
with disease severity is important in improving the health of aﬀected individuals. Epidemiological studies
have indicated that risk factors and behaviors are often “associated with both race or ethnicity and health
outcomes[,]” which may explain some of the racial health disparities.80 For example, one research study
“found that six well-established risk factors (tobacco use, hypertension, heperlipidemia, alcohol intake, ex-
cess weight, and diabetes mellitus) accounted for 31% of the excess mortality between Black and White
adults.”81 Racial diﬀerences, whether the result of genetics or environment, represent real diﬀerence in sus-
ceptibility to disease and potential response to a drug treatment regime.
While the racial diﬀerence in disease susceptibility or drug treatment eﬃcacy, the FDA should be hesitant
to approve race-speciﬁc drugs where the diﬀerences between racial populations is likely the result of envi-
ronmental factors, rather than genetic diﬀerences among races. Potentially eﬃcacious drugs will likely be
denied to individuals based on race even though they share similar socio-economic and environmental risk
factors that form the underlying basis of the racially diﬀerential eﬀect. Research indicates that “[c]ommon
diseases result from complex interactions between genetic and environmental factors.”82 Thus, even if an
individual possesses a gene associated with a disease, the patient will not necessarily develop the disease or
the severity disease symptoms will often depend on environmental factors. The signiﬁcant environmental
contribution to disease risk complicates the use of race as a proxy for an individual’s genetic composition.
As one researcher indicated “[t]he problem is that an individual’s response to a drug depends on a host
of factors, including overall health, lifestyle, support system, education, and socioeconomic status—all of
80Mays, supra note 22, at 86.
81Id.
82Tate, supra note 4, at S38.
22which are ...likely to be aﬀected, at least in the United States, by a person’s race.”83 While admittedly
researchers cannot control for every environmental factor, the FDA drug approval of race-speciﬁc drugs is
particularly problematic as race as seen by many particularly in the general public as a proxy for innate ge-
netic diﬀerences, which can entrench discriminatory racial stereotypes and race division, rather than merely
environmental diﬀerences. Any racial diﬀerences that researchers ﬁnd in occurrence rates of diseases or drug
responses may not be the result of some inherent genetic diﬀerence between racial populations, but partially
the result of environmental factors. For example, within the African American population, darker-skinned
Blacks generally have higher blood pressure than lighter-skinned Blacks.84 This diﬀerence in mean blood
pressure is not the direct result of skin color per se. Rather, according to researchers, “the association was
dependent on socioeconomic status, whether measured by education or an index consisting of education,
occupation, and ethnicity[.]”85 Lower socioeconomic status correlated with darker skin color as “darker skin
color in the United States is associated with less access to scarce and valued resources of the society.”86
Environmental factors, often associated with socioeconomic status and in part the product of racism, can
signiﬁcantly inﬂuence susceptibility to disease and drug treatment response.
To further illustrate the environmental contribution to disease, consider the disease, Asthma. The rate of
asthma in Black populations and White populations diﬀers by less than two percent.87 According to the
Center for Disease Control, however, Blacks are approximately three times more likely to be hospitalized
and die from Asthma than Whites.88 “These disease rate diﬀerences are of an entirely diﬀerent magnitude
from those associated with potential genetic diﬀerences between two populations, suggesting etiologies due to
83Anonymous, Genes, drugs, and race, 29 Nat. Genetics 239, 240 (2001).
84Duster, supra note 13, at 1051.
85M.J. Klag et al., The Association of Skin Color with Blood Pressure in US Black with Low Socioeconomic Status, 265 J.
of Am. Medical Assoc. 599, 599 (1991).
86Duster, supra note 13, at 1051.
87See L. Rhodes et al., Asthma Prevalence and Control Characteristics by Race/Ethnicity—United States, 2002, 53 Mor-
bidity & Mortality Weekly Report 145, 146 (2004) (7.6% of White, non-Hispanic reporting current Asthma compared to
9.3% of Black, non-Hispanic).
88See id. at 147; see also Arialdi M. Mini˜ no et al, Deaths: Final Data for 2000, 50 Nat’l Vital Statistics Report 1, 60
(2002) (death rate of 1.3% of Whites compared to 3.9% of Blacks).
23environmental diﬀerences of toxic exposures, housing quality, and access to health care.”89 Thus, the sever-
ity of asthma symptoms likely correlates with environmental factors that are more prevalent within certain
racial populations. As one researcher noted that for numerous complex genetic diseases, “many diﬀerences in
drug response associated with race or ethnicity are due to environmental correlates rather than population
genetic diﬀerences.”90 There is a recognition in the ﬁeld of epidemiology that environment is making a
signiﬁcant contribution to disease progression, and the goal of the research is to identify those environmental
factors. While the environmental risk factors may initially be identiﬁed in one racial category the ﬁnding
of environmental risk are applicable to anyone regardless of race in a similar environment. However, when
a drug company seeks and the FDA approves a drug for use in discrete racial populations, the FDA and
drug manufacturer are saying that there are innate diﬀerence between races, diﬀerences at the level of an
individual’s DNA. The racial diﬀerences in response to a drug could be 80% environmental (the FDA and
drug manufacturer would not know because there is no requirement to distinguish between environmental
and genetic contribution to the racial diﬀerence in drug response), but when the FDA approves the drug for
use in a single racial group, those who potentially could beneﬁt as they are exposed to similar environmental
factors will be denied unless a doctor chooses to prescribe the drug oﬀ-label.91
Some will argue that even if the racial diﬀerences in drug response or disease progression and severity are the
result of environmental factors, likely signiﬁcantly inﬂuenced by socioeconomics and racial discrimination,
the FDA approval of race-speciﬁc drugs is justiﬁed because regardless of cause, there are undeniable diﬀer-
ences in general between races. In regards to socioeconomic environmental factors, the problem is and “[i]t
is important to emphasize that race and ethnicity are distinct form socioeconomic status (i.e. income, edu-
89Jacqueline Stevens, Racial Meanings and Scientiﬁc Methods: Changing Policies for NIH-Sponsored Publications Reporting
Human Variation, 28 J. of Health Politics, Policy & Law 1033, 1069 (2003).
90Tate, supra note 4, at S37.
91See Krauss, supra note 12.
24cation, and occupation).”92 Minorities do disproportionately represent the lower levels of the United States
socioeconomic stratus. According to the 200 Census, approximately 22% of Blacks and 21% of Hispanics
were below the poverty line while only 9.4% of Whites (7.5% of White, Non-Hispanics) were below poverty
levels.93 However, when one looks at the individuals behind the percentages, while approximately 7,900,000
Blacks and 7,155,000 Hispanics were below the poverty line, so too were 21,291,000 Whites (14,572,000
White, Non-Hispanics).94 Socioeconomic status is “a robust predictor of access to and quality of health
care and education.”95 Environmental factors associated with poverty are not the result of genetics and
knows no racial lines. If the FDA approves race-speciﬁc drugs where environmental factors, particularly
environmental factors associated with socioeconomic status, form the basis for racial diﬀerences, the FDA
signiﬁcantly impedes the ability of other individuals in similar environmental situations to obtain eﬃcacious
drug treatments. Race may be a “quick and dirty way” of addressing environmental inﬂuences on drug re-
sponse or disease progression, but left behind are the potentially millions of other similarly situated, racially
diﬀerent individuals, who will be delayed and/or potentially foreclosed access to helpful treatment regimes.
The FDA should proceed judiciously when considering the approval of race-speciﬁc drugs and advocate for
an extremely limited use of race only upon showing of a scientiﬁc basis and necessity because racial diﬀer-
ences in drug response may in large part be the result of socioeconomic environmental factors, rather than
genetics diﬀerences, that know no race.
Race, Medicine, and Discrimination
92Jamie M. Doyle, What Race and Ethnicity Measure in Pharmacologic Research, 46 J. of Clinical Pharmacology, 401,
401 (2006).
93Joseph Dalaker, U.S. Census Bureau, Poverty in the United States: 2000, P60-214 Current Population Reports
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94Id.
95Burchard, supra note 50, at 1171.
25Race is a contentious concept within society that often results in discrimination even in the arena of health
care access and medicine. “It is indisputable that social perceptions of what a person is or is not [racially]
inﬂuences the availability, delivery, and outcome of medical care.”96 Based on race, “a physicians’ perception
of and interactions with a patient may diﬀer[.]”97 As a result, “[s]igniﬁcant disparities exist in health status,
health care utilization, and outcomes among diﬀerent racial and ethnic groups.”98 Even when patient, who
is a member of a minority racial group, has the same insurance coverage plan as a white patient, generally
the minority patient will receive fewer doctor visits, receive less primary care services, and less preventative
procedures.99 African-Americans upon hospitalization will receive “fewer surgical interventions, diagnostic
tests, medical services, and less optimal interventions than whites—even when their diagnosis, symptoms,
and source of payment are the same.”100 Particularly as these facts indicate there is a “synergistic combina-
tion of minority status and social class signiﬁcantly impedes improvements in health outcomes among racial
and ethnic minorities in the United States.”101 Minority racial groups disproportionately are represented
in the low echelons of the socioeconomic strata, as a result exposed to many negative environmental health
factors associated with poverty, and the risk of increased severity and prevalence of disease is only exacer-
bated by racism. Racial discrimination exists and is a problem within the medical health care industry.
The use of race in the FDA approval process may be important to ensure the health care needs of minority
U.S. racial populations are being met. “Although race or ethnicity, per se, is not casual, it may still function
as a risk indicator providing some reduction in uncertainty about the likelihood of morbidity or mortality.”102
Race may serve as an important crude indicator that allows physicians to better address the needs of their
96Schwartz, supra note 42, at 1392.
97Andrew J. Karter, Commentary: Race, Genetics, and Disease—In Search of a Middle Ground, 32 Int’l J. of Epidemi-
ology 26, 27 (2003).
98Lea Harty et al., Race and Ethnicity in the Era of Emerging Pharmacogenomics, 46 J. of Clinical Pharmacology 405,
405 (2006).
99Sidney D. Watson, Race, Ethnicity and Quality of Care: Inequalities and Incentives, 27 Am. J.L. & Med. 203, 205 (2001).
100Id. at 206.
101Doyle, supra note 92, at 401.
102Mays, supra note 22, at 85.
26patients. Further, as racial and ethnic minorities are often underrepresented in clinical trial, most drugs are
tested for safety and eﬃcacy on primarily white individuals.103 By impose additional regulations regarding
the use of race in the FDA approval process, one could argue that manufacturers will be less likely to inves-
tigate racial diﬀerences in disease and drug treatment eﬃcacy. Thus, factors result in racial diﬀerences in
disease or drug response, whether race speciﬁc or not, will never be identiﬁed.104 In addition, clinical data
regarding disease and drug treatments in minority U.S. racial subpopulations may be relevant in addressing
the medical needs of individuals who are of similar racial backgrounds in developing countries.105 There is a
legitimate argument that the FDA approval of race-speciﬁc drugs could be important in minimizing racism
and ensuring that drugs that are safe and eﬀective for minority racial groups.
While a legitimate argument can be made to not impose additional restrictions on FDA approval of race-
speciﬁc medicines, because of the potential for promoting racial discrimination and stereotyping, FDA should
further limit the FDA approval of race-speciﬁc drugs to instances where there is a clear scientiﬁc basis and
necessity particularly. While there is a history of inferior health care for minority races in the United States,
the FDA approval of race-speciﬁc drugs will not likely end racism within the scientiﬁc communities, but only
exacerbate the racial divide. The fear is that race-based medicines will lead to racial discrimination and
exacerbate racial disparities in medical care in three ways: (1) “heighten attention to biological diﬀerences
between groups by physicians,” (2) “increase the relatively high levels of distrust minorities already hold
toward the medical profession,” and (3) further entrench racial stereotypes and discrimination of the general
public by heightened attention to putative biological diﬀerences between races.106
The fear of increased racial disparities in health care by physicians based upon heightened attention to bio-
logical diﬀerences is not unfounded. The scientiﬁc and medical communities are not immune to the problems
103See Burchard, supra note 50, at 1174.
104Id.
105See Abdallah S. Daar & Peter A. Singer, Pharmacogenetics and Geographical Ancestry: Implications for Drug Development
and Global Health, 6 Nat. Rev. Genetics 241, 244 (2005).
106Condit, supra note 73, at 98.
27of race discrimination. The classic examples are the eugenics movement in the United States and around the
world and Holocaust in Nazi Germany. When the FDA approves a race-speciﬁc drug, the FDA is saying,
whether intentional or not, that a drug works for one racial group of people and not another. The FDA is
saying that there are fundamental, innate biological diﬀerences between the races in regards to eﬃcacy and
safety of a new drug. This is in spite of the lack of knowledge as to the true underlying cause of the disease—
proportional racial diﬀerences in environmental factors, genetic factors, or some combination of both that
result in the racial disparity in drug eﬀect.107 Doctors and other members of the medical community relying
upon the legislatively mandated role of the FDA in ensure only safe and eﬀective new drugs are approved
for public marketing will rely on the FDA-approved product insert indicating race-speciﬁc prescription of
the drug.108 Diﬀerent drug treatment regimes will be initiated based on race, a concept, as has already
been discussed in previous sections, of questionable scientiﬁc relevancy and validity in drug treatment. This
leads to “an easy slide down the slope to the misconceptions of “Black” or “White” diseases[,]” regardless
of whether the disease actually eﬀects members of multiple racial groups or the drug could beneﬁt members
of multiple racial populations.109 The FDA approval of race-speciﬁc drugs reinforces the notion that races
are inherently diﬀerent and has the potential for further widening of the medical services gap between some
minority races and Whites.
The FDA approval of race-speciﬁc drugs could further entrench the distrust of some minority racial popula-
tions feel towards the medical profession.110 Research studies indicate that minority trust in medical research
107One could similarly argue that the FDA approval of drugs based on gender carries the same potential for discrimination based
on public perception of innate biological diﬀerences and therefore, FDA approval and clinical testing on women as a subgroup
population should be limited. A key distinction, however, is that the terms male and female are not merely social constructs,
but are recognized by the scientiﬁc community to have a biological basis that result in innate physiological diﬀerences. See,
e.g. David D. Federman, The Biology of Human Sex Diﬀerences, 354 New Eng. J. of Med. 1507 (2006). Unlike gender, race
as discussed in previous section has debatable and limited scientiﬁc legitimacy as a term denoting biological and physiological
diﬀerences.
108See 21 U.S.C. § 355(d) (2004).
109Duster, supra note 13, at 1051.
110Sharona Hoﬀman, “Racially-Tailored” Medicine Unraveled, 55 Am. U. L. Rev. 395, 426 (2005); but see Wendler, supra note
14, at 7 (indicating that willingness to participate in medical trials was not the result of distrust of the medical profession, but
rather “substantial diﬀerences by race and ethnicity in the number of individuals invited to participate’ by medical researchers)
(emphasis in original text).
28and the medical profession generally, have been undermined by historic abuses like the Tuskegee syphilis
trials where African-Americans were not treated with available antibiotics known to cure the disease, but
instead allowed to progress to end-stage syphilis disease symptoms.111 The approval of race-speciﬁc drugs
does not quell minority distrust of the medical industry. According to one research survey, when asked
“’How suspicious would you be that a drug designated as preferred for African-Americans was not as safe as
a drug designated as preferred for European-Americans?’, 53% of African-American and 49% of all respon-
dents said they would be ’very supicious.’ Only 12% of both sets of respondents said that they would be
’not suspicious.”’112 In another study, after being asked to read a print message about a hypothetical drug,
’Fairdil,’ which stated that people of European and African ancestry may have diﬀerent responses to heart
medication and that “Fairdil has been shown to be more eﬀective for more African Americans in treating
high blood pressure”, only 20% of lay participants believed the message.113 The FDA approval of race-based
drugs may increase minority suspicion of the medical community and only intensify the disparity between
the races in regards to health care services.
Finally, the FDA approval of race-speciﬁc drugs may serve only to further entrench the inequity of medical
treatment and generally racial inequality in the United States society by heightening the attention of the
lay public to putative biological diﬀerences between races. When scientist report or, in particular, when the
FDA approves a drug advocating race-speciﬁc results without investigating further the basis of the racial
disparity in drug response, i.e. environmental or genetic factors, there is the potential that members of
the scientiﬁc and medical communities, and the public generally, will engage over in genetic reductionism.
“Public perception that scientiﬁc evidence has established that a particular ’race’ is more vulnerable to life-
threatening illnesses than others or does not respond to medications that cure most patients may reinforce
111See Giselle Corbie-Smith et al., Distrust, Race, and Research, 162 Archives of Int’l Medicine 2458, 2458 (2002).
112Condit, supra note 73, at 100 (quoting C.M. Condit et al., Exploration of the Impact of Messages about Genes and Race
on Lay Attitudes, 66 Clinical Genetics 402 (2004).
113Id. at 101 (quoting B.R. Bates et al., Evaluating Direct-to-Consumer Marketing of Race-based Pharmacogenomics: A focus
Group Study of Public Understanding of Applied Genomic Medications, 9 J. of Health Commun. 541 (2004))
29negative ’race-based’ stereotypes and misconceptions. Particular populations may be seen as diseased or
incurable.”114 This can lead to stigmatization not only in the general public, both also at the oﬃce and
in regards to procuring health and/or life insurance. Employers and insurers may discriminate based upon
lower potential employee productivity because of absences or require a higher premium to be paid based on
the racial population an individual belongs to regardless of whether the individual is actually predisposed
to a disease or will respond to treatment. Mere membership in the larger racial group will result in the
individual patient having their health risk stereotyped. “There is a tendency for scientists to ignore the
messy social implications of what they do.”115 However, there are undeniable series implications regarding
the potential for racial discrimination that the FDA, as an agency possessing scientiﬁc and policy expertise,
should consider before continuing down the path to further approvals of race-speciﬁc drugs.
Legal Authority
As advocated throughout this paper, when considering the approval of race-speciﬁc drugs, the FDA should
implement a public policy with an extremely limited use of race only upon showing of scientiﬁcally signif-
icant data demonstrating a racially diﬀerential eﬀect and the need to rely on race in the absence of any
other available population markers. However, a fundamental question remains of whether the FDA is legally
authorized in withholding new drug application approval based on failure to present data showing a racially
diﬀerential eﬀect of the drug. While the FDA generally has considerable agency discretion in creating regu-
latory policy through both the text of the organic agency statute and the Administration Procedure Act, a
strong argument can be made that the FDA lacks the statutory basis for authority to require manufacturers
undertake clinical trials to show statistically signiﬁcant data demonstrating a racially diﬀerential eﬀect.
114Hoﬀman, supra note 110, at 423.
115Richard S. Cooper et al, Race and Genomics, 348 New Eng. J. of Med. 1166, 1169 (2003).
30The basis for the argument that the FDA cannot impose restrictions on the use of race during the FDA
approval process is based on the reasoning in the district court decision in Ass’n of American Physicians
and Surgeons, Inc. v. United States Food and Drug Administration.116 In the case, the FDA regulations
“requiring drug manufacturers to conduct drug tests on pediatric populations and suggest pediatric doses
for drugs,” even though the drugs were intended for adult populations, was challenged as exceeding the
FDA’s congressional grant of authority and being arbitrary and capricious.117 The district court ruled that
the pediatric regulation exceeded FDA’s statutory authority. In reaching this decision, the district court
found the labeling provisions 21 U.S.C. §§ 352(a), 352(f), 355(d)(7), and 321(n), requiring the labeling to
reveal material “facts ...under such conditions of use as are customary or usual,” did not vest the FDA with
the power to promulgate the Pediatric Rule.118 The court focused on the language “customary or usual”
in the text of the statute and indicated that new drugs “do not have any customary or usual use,” so this
does not establish a clear basis for the Pediatric Rule.119 The FDA also relied upon 21 U.S.C. §§ 321(p),
331(a) and (d) and 355 (a), (j), and (d), which requires the manufacturer of a new drug to demonstrate that
the product is safe “for use under the conditions prescribed, recommended, or suggested in the purposed
labeling thereof.” 120 The court disagreed with the FDA’s reliance on §§ 355(d) and 321(p) indicating that
the Pediatric Rule goes beyond the statutory requirement by requiring “manufacturers to test products for
use on children, even if such a use is not prescribed, recommended, or suggested by the products’ label.”121
Finally, the court addressed whether the Pediatric Rule promulgated “ﬁt[s] into the overall regulatory scheme
created by Congress.”122 The court reasoned that if Congress enacted a distinct regulatory scheme on the
given issue, “Congress demonstrates its intention to occupy the ﬁeld, and any attempt by the FDA to inter-
116226 F.Supp.2d 204 (D.C. 2002).
117Id. at 204.
11821 U.S.C. § 321(n)
119Ass’n of Am. Physicians & Surgeons, 226 F.Supp.2d at 214.
120Id.
121Ass’n of Am. Physicians and Surgeons, 226 F.Supp.2d at 215.
122Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155, 163 (4th Cir. 1998) aﬀ’d 529 U.S. 120 (2000).
31vene with an inconsistent regime shall be deemed in excess of its authority.”123 The court found that the
passage of the Best Pharmaceuticals for Children Act (BPCA), Congress expressed its intent to occupy the
ﬁeld.124 Further, the BPCA and the FDA’s Pediatric Rule, according to the court, are incompatible because
“the very thrust of the BPCA—providing marketing incentives to encourage voluntary testing—is entirely
anomalous with the very thrust of the Pediatric Rule—requiring such tests in the absence of a deferral or
waiver.”125 For the foregoing reasons, the district court found the FDA exceeded its authority by promul-
gating the Pediatric Rule requiring drug manufacturers to test on pediatric populations.126
The Ass’n of American, Physicians and Surgeons case calls into question the ability and authority of the
FDA to require clinical data indicating a clear scientiﬁc basis and necessity for the reliance on race. First,
one should note that Ass’n of American, Physicians and Surgeons, the district court indicated the ques-
tion of whether the FDA had authority to require pediatric drug testing “is a close one[.]”127 Further, the
“opinion was the work of a lone district court judge.” 128 Based on public policy and the broad statutory
language of the Federal Food, Drug, and Cosmetic Act (“FDCA”), one could argue that Ass’n of American,
Physicians and Surgeons was wrongly decided. The FDA should be allowed to require clinical testing in
special populations as a condition for FDA approval subject to review under an arbitrary and capricious
standard. Alternatively, one could argue that the Ass’n of American, Physicians and Surgeons decision in
the context of pediatric drugs is distinguishable from the context of race-based drugs. However, the case
advocating for the ability of the FDA to regulate the use of race and requiring clinical trial data showing
a diﬀerential racial eﬀect of drugs to support the use of race in labeling is stronger than in the pediatric
123Ass’n of Am. Physicians and Surgeons, 226 F.Supp.2d at 219.
124Id. at 221.
125Id.
126Id. at 222.
127Id. at 213.
128Charlie Steenberg, The FDA’s Use of Postmarketing (“Phase IV”) Study Requirements: Exception to Rule and Promise to Problem
at 107 (2005), in Peter Barton Hutt, ed., Food and Drug Law: An Electronic Book of Student Papers, available at
http://leda.law.harvard.edu/leda/search/toc.php3?handle=HLS.Library.Leda/steenburgc-fdas use postmarketing.
32drug context. While beyond the scope of this paper, there are credible arguments, not presented in Ass’n
of American, Physicians and Surgeon, that the FDCA empowers the FDA to require testing in subpopula-
tions not mentioned in its labeling, or even disclaimed, under § 502(f) and (k).129 Further, the decision in
Ass’n of American, Physicians and Surgeon “turned at least in part on the tension between the pediatric
rule’s mandatory requirements for pediatric studies and the [BPCA’s] incentive-laden scheme for encourag-
ing them.”130 Unlike in the context of pediatric drugs, Congress has not explicitly expressed its intent to
regulate race-speciﬁc drugs. No marketing incentive similar to the BPCA has been proposed by Congress
to incentivize manufacturers to test drugs in speciﬁc racial populations. As a part of the Food and Drug
Modernization Act (FDMA) of 1997, Congress amended § 355(b)(1) to include the language, “The Secretary
shall ...review and develop guidance, as appropriate, on the inclusion of women and minorities in clinical
trials ....”131 Thus, contrary to the FDA requirements for pediatric trials, Congress has not developed a
speciﬁc scheme to monitor the use of race in clinical trials as in the case of BPCA. The text of the statute
grants authority to the FDA to issue guidance related to the inclusion of minorities. Further, while Congress
did not speciﬁcally delegate authority to the FDA to regulate the inclusion of minorities based on the text of
FDMA, neither does the statute prohibit the FDA from developing regulations regarding race-speciﬁc drugs
to the FDA. Ass’n of American, Physicians and Surgeon does not unequivocally foreclose the ability of the
FDA to oﬀer policy guidance and regulate the use of race and prose clinical testing requirements when race
is used, but the extent of FDA’s legal and statutory authority to promulgate clinical testing requirements is
questionable and debatable.
Also, unlike in the context of pediatric drugs, the use of race in clinical trials and in the context of FDA drug
129Id.; See, e.g. Derek Ho, Adopting the Therapeutic Orphan? A Legal and Regulatory Assessment of the FDA’s Pedi-
atric testing Rule (2000), in Peter Barton Hutt, ed., Food and Drug Law: An Electronic Book of Student Papers, available at
http://leda.law.harvard.edu/leda/search/toc.php3?handle=HLS.Library.Leda/hod-adopting therapeutic orphan.
130Steenberg, supra note 128, at 107.
131Admittedly, the statutory language “inclusion of women and minorities” is ambiguous in respect to whether “minorities”
are to be treated as a single class or distinct racial classes.
33approval raises serious potential Equal Protection Clause issues under the Fourteenth Amendment of the
U.S. Constitution. The Equal Protection Clause provides that no state shall “deny to any person within its
jurisdiction equal protection under the law.”132 The Supreme Court has indicated that “racial classiﬁcations
imposed by the government must be analyzed by a review court under strict scrutiny” and “such “classiﬁ-
cations are constitutional only if they are narrowly tailored to further a compelling government interest.”133
Some commentators have contended that the FDA is legally prohibited from approving race-speciﬁc drugs
and argued the viability of the Equal Protection Clause and a number of federal anti-discrimination provi-
sions that could be violated by the FDA approval of race-based medicines.134 While I disagree that the use
of race in the FDA approval process is per se unconstitutional and recognize that the text of the FDCA on
its face is unconstitutional, one could argue that the application of FDA approval authority of race-speciﬁc
drugs under §355(c) and (d) is government action utilizing race and thus subject to strict scrutiny analysis.
In order for the FDA action and the use of race in drug approval to be found constitutional under the Equal
Protection Clause of the U.S. Constitution, there must be a compelling government interest and the use of
race must be narrowly tailored.135
While the health and safety of racial subpopulations is a compelling government interest, it is unclear if
the FDA has met the second requirement of the Equal Protection Clause analysis—the narrow tailoring
requirement. The purpose of the narrow tailoring requirement “is to ensure that the means chosen ﬁt the
compelling goal so closely that there is little or no possibility that the motive for the classiﬁcation was
illegitimate racial prejudice or stereotype.”136 As people are being potentially denied life saving drugs based
on race unless doctors know that the drug may be eﬀective in other races and is willing to prescribe the drug
132U.S. Const. Amend. 14, §2.
133Grutter v. Bollinger, 539 U.S. 306, 326 (2003).
134For an excellent and insightful review of potential federal causes of action in regards to race-speciﬁc medicines, i.e. Consti-
tutions Equal Protection Clause, 42 U.S.C. §1981, and Civil Rights Act of 1964, see Lillquist, supra note 13, at 442-466.
135See Grutter, 539 U.S. at 327.
136Id. at 333.
34oﬀ-label, the automatic FDA approval of drugs for uses and indications within speciﬁc racial populations
without a showing of any statistically signiﬁcant data indicating the need to rely on the proposed racial
distinction could be argued to violate the Equal Protection Clause by failing to meet the narrowly tailored
requirement. The FDA arguable is required to preserve the constitutionality of its race-speciﬁc drug approval
actions by narrowly tailoring the use of race. As such, one could argue that limiting the approval of new
drug application targeted to speciﬁc racial population to situations where there is a clear scientiﬁc basis for
the reliance on race and necessity as shown by the lack of any other known, correlating clinical markers is
required to ensure the FDA does not violate the Equal Protection Clause.
The legal statutory and constitutional legitimacy and authorization of the FDA to require drug manufac-
turers to show a scientiﬁc basis for the reliance on race is debatable. To clearly resolve this issue without
litigation, congressional action may be required to establish a framework to guide the FDA in its approval
of race-speciﬁc medicines or to speciﬁcally grant authority to the FDA to develop race speciﬁc drugs. In-
terestingly, in the context of pediatric drugs, after Ass’n of American, Physicians and Surgeon, a group of
Senators “savaged” the Ass’n of American, Physicians and Surgeon decision as “ill-considered and obviously
errant.”137 Further, the case resulted “in the 2003 PREA, which clearly authorized certain Phase IV studies
by giving the power to require (and defer) pediatric trials in limited circumstances.”138 The foregoing de-
scribes the potential limitations and legal issues surround the FDA’s congressionally delegated authority to
require statistically signiﬁcant data showing race diﬀerential eﬀects. However, based on the statutory dis-
tinctions between pediatric drugs and race-speciﬁc drugs and the U.S. Constitution Equal Protection Clause
arguments, there is a reasonable legal basis for requiring drugs a clear scientiﬁc basis for the reliance on race,
such as data indicating racially diﬀerent responses to a drug, before drugs are approved to be marketed and
used in racial subpopulations.
137Steenberg, supra note 128, at 107.
138Id.
35Recommendations
The FDCA vests in the Secretary of Health and Human Services, who operates through the FDA, authority
to approve new drugs.139 Pursuant to the FDCA, drug manufacturers are required to receive premarket
approval of candidate drugs by submitting a full report showing that the drug is safe and eﬀective for the
intended use.140 The FDA drug approval process serves as the gatekeeper to ensure that safe and eﬀective
drugs are made available to the United States public regardless of race. Recognizing that there may be some
biological relevance to racial categorization and current general infeasibility of pharmacogenomics, I would
advocate for the FDA to narrowly tailor the use of race and limit race-speciﬁc claims in FDA drug approval
to situations in which there is a clear scientiﬁc basis and necessity for the reliance on race. The FDA could
evaluate the scientiﬁc basis and necessity of race by utilizing scientiﬁc advisory panels pursuant to 21 U.S.C.
§ 355(n), who based on the evidence presented at the drug approval process and their scientiﬁc expertise
could access these criteria. Any racial disparity would need to be shown on a statistically signiﬁcant patient
population.141 Further, the term race, as utilized in any clinical trial, and the manner in which patient
participants where classiﬁed in regards to race should be clearly deﬁned.
As an example of how review of a drug application for a race-speciﬁc medicine would occur using the
narrowly tailored recommendation consider the case of BiDilr . Applying the requirements for statistically
signiﬁcant clinical data demonstrating racial diﬀerences and the necessity to rely on race as a marker, BiDilr 
would still be approved by the FDA. Clinical testing of BiDilr  in a mixed-population (primarily white)
revealed therapeutic diﬀerences that were only of border-line statistical signiﬁcance in the ﬁrst trial.142
139See 21 U.S.C. § 371 (2004).
140See 21 U.S.C. § 355(d) (2004),
141Under the current FDA guidelines, the racial and ethnic identity of clinical trial participants is to be recorded but there
is no requirement that there be statistically signiﬁcant numbers of any racial group participating in the clinical trial. See
FDA, supra note 17. While beyond the scope of this paper, the mere requirement of reporting subpopulation identity without
requiring statistically signiﬁcant numbers of individuals from any one subpopulation does not allow for scientiﬁc conclusions to
be drawn comparing races because any race-speciﬁc data generated from the trial may not statistically signiﬁcant.
142Kahn, supra note 5, at 12. Please note that in the second clinical trial, there were too many variables in the protocol at
36When tested on self-identiﬁed Blacks, the eﬃcacy of the drug was statistically signiﬁcant.143 Therefore,
BiDilr  manufacturers have demonstrated that there is a scientiﬁc basis for the use of race as evident by
the racial diﬀerences in drug response. In regards to the second prong of the narrowly tailored use of race
recommendation, necessity for reliance on race, there is speculation that the eﬃcacy of BiDilr  in Blacks is
based on a nitric oxide deﬁciency.144 While there is speculation that nitric oxide levels could serve as a non-
racial marker, there is currently no genetic determinate linked to nitric oxide levels and BiDilr  response, and
there is no easy method biochemically to measure nitric oxide levels. Therefore, reliance on race as a crude
marker currently is necessary because no other non-racial population markers are available. While the action
of BiDilr  manufacturers in moving toward the racialization of the drug (procuring a signiﬁcant extension in
patent term and characterization of heart disease in blacks) may be motivated by economic considerations,
as BiDil was shown to have statistically signiﬁcant diﬀerences in eﬃcacy between racial populations and
because non-racial population markers are currently unavailable, BiDilr  would be approved by the FDA
under the recommended narrowly tailored regime of approving race-speciﬁc drugs.
Conclusions
Race is a violatile social concept in the United States of which the scientiﬁc basis of race as a biologically
signiﬁcant categorization is hotly debated. The delineation of racial populations has changed throughout
U.S. history and with the ever increasing population of multiracial individuals in the United States the line
dividing racial populations is likely to blur even more. Genetically, race tends to be a very crude proxy for
primary end points to interpret the data. Id. at 15.
143See Anne L. Taylor et al., Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure, 351 New
Eng. J. of Med. 2049 (2004).
144See Rotman, supra note 12.
37genetic variation. The limited usefulness of race as a genetic proxy is compounded by the fact that population
diﬀerences for most complex disease genes will be the result, as least in part, of environmental factors. These
environmental disease risk factors are often disproportionately prevalent in minority populations due to racial
discrimination and socioeconomic disadvantage. Unfortunately, racial discrimination may only be further
entrenched by the FDA approval of race-speciﬁc drugs as it may validate racist and eugenic ideological beliefs
that that there are innate genetic diﬀerence between racial populations. As this paper attempted to illustrate
and likely inevitably oversimpliﬁed, the complexity of the term “race,” both socially and scientiﬁcally, is
immense. Recognizing the complexity of race within the United States, the FDA should proceed cautiously
in the further approval of race-speciﬁc drugs and review of race-speciﬁc new drug applications under a strict
scrutiny regime. As drug manufacturers are making more race-speciﬁc drug claims, the issue of race-speciﬁc
drugs is likely to arise more frequently within the FDA. The FDA needs to now develop and articulate a
framework to guide the approval of race-speciﬁc medicines that minimizes the potential for discrimination
and reinforcement of racist beliefs while still making safe and eﬃcacious drugs available to all. In accords
with a strict scrutiny analysis and narrowly tailored use of race, the FDA should judiciously limit the FDA
approval of race-speciﬁc drugs to situations in which the utilization of racial categories is based on statistically
signiﬁcant scientiﬁc data and necessity to ensure that access to safe and eﬃcacious drugs is not a black and
white issue.
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